Cargando…

Personalized glucose-lowering effect of chiglitazar in type 2 diabetes

Chiglitazar (carfloglitazar) is a peroxisome proliferator-activated receptor pan-agonist presenting non-inferior glucose-lowering efficacy with sitagliptin in patients with type 2 diabetes. To delineate the subgroup of patients with greater benefit from chiglitazar, we conducted a machine learning-b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Qi, Zou, Xiantong, Chen, Yingli, Gao, Leili, Cai, Xiaoling, Zhou, Lingli, Gao, Fei, Zhou, Jian, Jia, Weiping, Ji, Linong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628820/ https://www.ncbi.nlm.nih.gov/pubmed/37942014 http://dx.doi.org/10.1016/j.isci.2023.108195

Ejemplares similares

How does obesity affect mortality through blood pressure and blood glucose in Chinese and US citizens? Insights from a causal mediation analysis of two large cohorts
por: Huang, Qi, et al.
Publicado: (2023)

Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis
por: Lin, Chu, et al.
Publicado: (2023)

In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
por: He, B. K., et al.
Publicado: (2012)

Do East Asians With Normal Glucose Tolerance Have Worse β-Cell Function? A Meta-Analysis of Epidemiological Studies
por: Li, Li, et al.
Publicado: (2021)

Associated Factors with Biochemical Hypoglycemia during an Oral Glucose Tolerance Test in a Chinese Population
por: Cai, Xiaoling, et al.
Publicado: (2017)

The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004
por: Li, Li, et al.
Publicado: (2022)

No disparity of the efficacy and all‐cause mortality between Asian and non‐Asian type 2 diabetes patients with sodium–glucose cotransporter 2 inhibitors treatment: A meta‐analysis
por: Cai, Xiaoling, et al.
Publicado: (2017)

Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis
por: Cai, Xiaoling, et al.
Publicado: (2016)

Comparative Evaluation of Chiglitazar and Sitagliptin on the Levels of Retinol-Binding Protein 4 and Its Correlation With Insulin Resistance in Patients With Type 2 Diabetes
por: Zhou, Yunting, et al.
Publicado: (2022)

NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?—Results From NHANES III
por: Huang, Qi, et al.
Publicado: (2021)

Review: Machine learning in precision pharmacotherapy of type 2 diabetes—A promising future or a glimpse of hope?
por: Zou, Xiantong, et al.
Publicado: (2023)

Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis
por: Cai, Xiaoling, et al.
Publicado: (2017)

P38 Plays an Important Role in Glucolipotoxicity-Induced Apoptosis in INS-1 Cells
por: Zhou, Lingli, et al.
Publicado: (2014)

Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study
por: Zhou, Lingli, et al.
Publicado: (2019)

The association between self-monitoring of blood glucose and HbA1c in type 2 diabetes
por: Yuan, Yanping, et al.
Publicado: (2023)

A Decision-Support Software to Improve the Standard Care in Chinese Type 2 Diabetes
por: Luo, Yingying, et al.
Publicado: (2019)

Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ
por: Pan, De-Si, et al.
Publicado: (2017)

Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes
por: Wang, Yanai, et al.
Publicado: (2019)

The Association of Retinopathy and Plasma Glucose and HbA1c: A Validation of Diabetes Diagnostic Criteria in a Chinese Population
por: Zhang, Rui, et al.
Publicado: (2016)

To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations
por: Sullivan, Holli-Joi, et al.
Publicado: (2020)

Age at Diagnosis and C-Peptide Level Are Associated with Diabetic Retinopathy in Chinese
por: Cai, Xiaoling, et al.
Publicado: (2014)

Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes
por: Huang, Xiuting, et al.
Publicado: (2018)

Silent hemoglobin variant during capillary electrophoresis: A case report
por: Yuan, Yanping, et al.
Publicado: (2020)

Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis
por: Cai, Xiaoling, et al.
Publicado: (2018)

Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
por: Cai, Xiaoling, et al.
Publicado: (2021)

Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic Population
por: Zhu, Yu, et al.
Publicado: (2019)

The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2022)

The characteristics of newly diagnosed adult early-onset diabetes: a population-based cross-sectional study
por: Zou, Xiantong, et al.
Publicado: (2017)

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
por: Lin, Chu, et al.
Publicado: (2021)

Contribution of mitochondrial gene variants in diabetes and diabetic kidney disease
por: Li, Meng, et al.
Publicado: (2022)

Estimation of atherosclerotic cardiovascular disease risk in type 2 diabetes
por: Cai, Xiaoling, et al.
Publicado: (2022)

Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis
por: Lin, Chu, et al.
Publicado: (2021)

Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
por: Yang, Wenjia, et al.
Publicado: (2017)

Sex differences in the prevalence of obesity in 800,000 Chinese adults with type 2 diabetes
por: Lv, Fang, et al.
Publicado: (2021)

Human Gut Microbiota Changes Reveal the Progression of Glucose Intolerance
por: Zhang, Xiuying, et al.
Publicado: (2013)

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis
por: Hu, Mengdie, et al.
Publicado: (2020)

Clinical Characteristics of Young Type 2 Diabetes Patients with Atherosclerosis
por: Yang, Wenjia, et al.
Publicado: (2016)

Analysis of Insulin Doses of Chinese Type 2 Diabetic Patients with Intensive Insulin Treatment
por: Cai, Xiaoling, et al.
Publicado: (2012)

Comparisons of the Efficacy of Alpha Glucosidase Inhibitors on Type 2 Diabetes Patients between Asian and Caucasian
por: Cai, Xiaoling, et al.
Publicado: (2013)

Preserved C-peptide secretion is associated with higher time in range (TIR) on intermittently scanned continuous glucose monitoring in Chinese adults with type 1 diabetes
por: Liu, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ttq7kc5f34opfliv3josu0nvak